{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:34:45Z","timestamp":1793932485020,"version":"4.8.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cedars Sinai Cancer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite great interest, there is limited clinical evidence to support the use of a ketogenic diet (KD) for cancer patients. We conducted a single-arm phase 1 trial of a KD among patients with recently diagnosed glioblastoma (GBM) receiving standard-of-care (SOC) treatment. Adults with GBM within 3 months of diagnosis followed a supervised 16-week intervention of a 3:1 KD (Fat(g): Carbohydrate\u2009+\u2009Protein(g)) plus SOC chemoradiation. The primary outcome was safety, evaluated by weekly assessments of weight and body mass index (BMI). Secondary outcomes included feasibility (pre-specified as &gt;\u200950% of patients maintaining blood ketone levels\u2009&gt;\u20090.3 mM over 50% of study days), progression-free survival (PFS), overall survival (OS), health-related quality-of-life, and cognitive function. Twice daily blood glucose and ketones, weight\/BMI, physical activity, and sleep were assessed by remote monitoring. Seventeen patients were evaluable: 53% women, median age 55, median Karnofsky Performance Status 85. All subjects met the primary safety objective with no instances of excessive weight loss or related serious adverse events. Adherence was high: all 17 patients maintained nutritional ketosis (\u2265\u20090.3 mM\/dL)\u2009&gt;\u200950% of study days. Median PFS and OS were 12.9 months and 29.4 months from KD initiation respectively. Quality of Life, symptom control, and cognitive function remained stable or improved, although these did not reach statistical significance. This phase 1 trial demonstrates that KD is safe and feasible for GBM patients receiving SOC, may improve outcomes, and provides a foundation for an NCI-funded multicenter randomized diet trial to assess efficacy that is currently underway.<\/jats:p>","DOI":"10.1038\/s41598-025-06675-6","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:37:58Z","timestamp":1751369878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma"],"prefix":"10.1038","volume":"15","author":[{"given":"L. J.","family":"Amaral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Gresham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad","family":"Tighiouart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Welborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lockshon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Noorvash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Rudnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jethro","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"10","key":"6675_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"Mar 10","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl. J. Med. Mar 10 (10), 987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330 (2005).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"6675_CR2","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1542\/peds.105.4.e46","volume":"105","author":"F Lefevre","year":"2000","unstructured":"Lefevre, F. & Aronson, N. Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efficacy. Pediatrics 105 (4), e46\u2013e46. https:\/\/doi.org\/10.1542\/peds.105.4.e46 (2000).","journal-title":"Pediatrics"},{"issue":"3191","key":"6675_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"24","author":"O Warburg","year":"1956","unstructured":"Warburg, O. On the origin of cancer cells. Science Feb. 24 (3191), 309\u2013314. https:\/\/doi.org\/10.1126\/science.123.3191.309 (1956).","journal-title":"Science Feb"},{"issue":"5930","key":"6675_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"22","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science May. 22 (5930), 1029\u20131033. https:\/\/doi.org\/10.1126\/science.1160809 (2009).","journal-title":"Science May"},{"key":"6675_CR5","doi-asserted-by":"publisher","unstructured":"Nebeling, L. C., Miraldi, F., Shurin, S. B. & Lerner, E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J. Am. Coll. Nutr. 14 (2), 202\u2013208. https:\/\/doi.org\/10.1080\/07315724.1995.10718495 (1995).","DOI":"10.1080\/07315724.1995.10718495"},{"key":"6675_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1743-7075-7-33","volume":"7","author":"G Zuccoli","year":"2010","unstructured":"Zuccoli, G. et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab. (Lond) Apr. 7, 33. https:\/\/doi.org\/10.1186\/1743-7075-7-33 (2010).","journal-title":"Nutr Metab. (Lond) Apr"},{"key":"6675_CR7","doi-asserted-by":"publisher","first-page":"175883591985395","DOI":"10.1177\/1758835919853958","volume":"11","author":"EJTM van der Louw","year":"2019","unstructured":"van der Louw, E. J. T. M. et al. Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study. Ther. Adv. Med. Oncol. 11, 1758835919853958. https:\/\/doi.org\/10.1177\/1758835919853958 (2019).","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"6675_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11060-020-03417-8","volume":"147","author":"KJ Martin-McGill","year":"2020","unstructured":"Martin-McGill, K. J. et al. Ketogenic diets as an adjuvant therapy for glioblastoma (KEATING): a randomized, mixed methods, feasibility study. J Neurooncol Mar. 147 (1), 213\u2013227. https:\/\/doi.org\/10.1007\/s11060-020-03417-8 (2020).","journal-title":"J Neurooncol Mar."},{"key":"6675_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3389\/fnins.2020.00390","volume":"14","author":"CM Panhans","year":"2020","unstructured":"Panhans, C. M., Gresham, G., Amaral, J. L. & Hu, J. Exploring the feasibility and effects of a ketogenic diet in patients with CNS malignancies: A retrospective case series. Front. Neurosci. 14, 390. https:\/\/doi.org\/10.3389\/fnins.2020.00390 (2020).","journal-title":"Front. Neurosci."},{"key":"6675_CR10","doi-asserted-by":"crossref","unstructured":"Volek, J. S., Noakes, T. & Phinney, S. D. Rethinking fat as a fuel for endurance exercise. Europ. J. Sport Sci. 15 (1):1320. doi:10.1080\/17461391.2014.959564. (2015)","DOI":"10.1080\/17461391.2014.959564"},{"key":"6675_CR11","doi-asserted-by":"publisher","unstructured":"Hagihara, K. et al. Promising effect of a new ketogenic diet regimen in patients with advanced cancer. Nutrients May. 19 (5). https:\/\/doi.org\/10.3390\/nu12051473 (2020).","DOI":"10.3390\/nu12051473"},{"key":"6675_CR12","doi-asserted-by":"publisher","unstructured":"Klement, R. J., Sch\u00e4fer, G. & Sweeney, R. A. A ketogenic diet exerts beneficial effects on body composition of cancer patients during radiotherapy: an interim analysis of the KETOCOMP study. J. Tradit Complement. Med. 10 (3), 180\u2013187. https:\/\/doi.org\/10.1016\/j.jtcme.2019.03.007 (May 2020).","DOI":"10.1016\/j.jtcme.2019.03.007"},{"issue":"1","key":"6675_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/obr.12230","volume":"16","author":"AA Gibson","year":"2015","unstructured":"Gibson, A. A. et al. Do ketogenic diets really suppress appetite? A systematic review and meta-analysis. Obes. Rev. 16 (1), 64\u201376. https:\/\/doi.org\/10.1111\/obr.12230 (2015).","journal-title":"Obes. Rev."},{"key":"6675_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fnut.2018.00011","volume":"5","author":"KA Schwartz","year":"2018","unstructured":"Schwartz, K. A., Noel, M., Nikolai, M. & Chang, H. T. Investigating the ketogenic diet as treatment for primary aggressive brain cancer: challenges and lessons learned. Front. Nutr. 5, 11. https:\/\/doi.org\/10.3389\/fnut.2018.00011 (2018).","journal-title":"Front. Nutr."},{"issue":"2","key":"6675_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson, B. M., Wen, P. Y. & Cloughesy, T. F. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics Apr. 14 (2), 307\u2013320. https:\/\/doi.org\/10.1007\/s13311-016-0507-6 (2017).","journal-title":"Neurotherapeutics Apr"},{"issue":"3","key":"6675_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1467-9876.2005.00510.x","volume":"54","author":"RA Rigby","year":"2005","unstructured":"Rigby, R. A. & Stasinopoulos, D. M. Generalized additive models for location, scale and shape. J. Roy. Stat. Soc.: Ser. C (Appl. Stat.). 54 (3), 507\u2013554. https:\/\/doi.org\/10.1111\/j.1467-9876.2005.00510.x (2005).","journal-title":"J. Roy. Stat. Soc.: Ser. C (Appl. Stat.)"},{"key":"6675_CR17","doi-asserted-by":"publisher","unstructured":"Rigby, R. A. & Stasinopoulos, D. M. Automatic smoothing parameter selection in GAMLSS with an application to centile estimation. Stat. Meth. Med. Res. (2014). https:\/\/doi.org\/10.1177\/0962280212473302","DOI":"10.1177\/0962280212473302"},{"key":"6675_CR18","doi-asserted-by":"publisher","unstructured":"van Buuren, S. & Fredriks, M. Worm plot: a simple diagnostic device for modelling growth reference curves. Stat Med 20 (8) 1259-77. (2001). https:\/\/doi.org\/10.1002\/sim.746","DOI":"10.1002\/sim.746"},{"issue":"8","key":"6675_CR19","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncology 23 (8), 1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106 (2021).","journal-title":"Neuro-Oncology"},{"issue":"7719","key":"6675_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","volume":"08","author":"BD Hopkins","year":"2018","unstructured":"Hopkins, B. D. et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 08 (7719), 499\u2013503. https:\/\/doi.org\/10.1038\/s41586-018-0343-4 (2018).","journal-title":"Nature"},{"issue":"5","key":"6675_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41574-020-0329-9","volume":"05","author":"BD Hopkins","year":"2020","unstructured":"Hopkins, B. D., Goncalves, M. D. & Cantley, L. C. Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer. Nat. Rev. Endocrinol. 05 (5), 276\u2013283. https:\/\/doi.org\/10.1038\/s41574-020-0329-9 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"6675_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12885-016-2337-7","volume":"05","author":"DM Lussier","year":"2016","unstructured":"Lussier, D. M. et al. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer. 05, 16:310. https:\/\/doi.org\/10.1186\/s12885-016-2337-7 (2016).","journal-title":"BMC Cancer"},{"issue":"7519","key":"6675_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature Sep. 513 (7519), 559\u2013563. https:\/\/doi.org\/10.1038\/nature13490 (2014).","journal-title":"Nature Sep."},{"key":"6675_CR24","doi-asserted-by":"publisher","unstructured":"Hirschberger, S. et al. Very-low-carbohydrate diet enhances human T-cell immunity through immunometabolic reprogramming. EMBO Mol. Med.  https:\/\/doi.org\/10.15252\/emmm.202114323","DOI":"10.15252\/emmm.202114323"},{"key":"6675_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1743-7075-7-74","volume":"7","author":"P Stafford","year":"2010","unstructured":"Stafford, P. et al. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab. (Lond) Sep. 7, 74. https:\/\/doi.org\/10.1186\/1743-7075-7-74 (2010).","journal-title":"Nutr Metab. (Lond) Sep."},{"issue":"1","key":"6675_CR26","doi-asserted-by":"publisher","first-page":"12277","DOI":"10.1038\/s41598-019-48794-x","volume":"08","author":"HE Lee","year":"2019","unstructured":"Lee, H. E. et al. Inhibition of NLRP3 inflammasome in tumor microenvironment leads to suppression of metastatic potential of cancer cells. Sci. Rep. 08 (1), 12277. https:\/\/doi.org\/10.1038\/s41598-019-48794-x (2019).","journal-title":"Sci. Rep."},{"issue":"3","key":"6675_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"YH Youm","year":"2015","unstructured":"Youm, Y. H. et al. The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med Mar. 21 (3), 263\u2013269. https:\/\/doi.org\/10.1038\/nm.3804 (2015).","journal-title":"Nat Med Mar."},{"issue":"6116","key":"6675_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1126\/science.1227166","volume":"339","author":"T Shimazu","year":"2013","unstructured":"Shimazu, T. et al. Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science Jan. 339 (6116), 211\u2013214. https:\/\/doi.org\/10.1126\/science.1227166 (2013).","journal-title":"Science Jan"},{"key":"6675_CR29","doi-asserted-by":"crossref","unstructured":"Qin, J. et al. Ketogenic diet reshapes cancer metabolism through lysine \u03b2-hydroxybutyrylation. Nat. Metabol. 6 (8)15051528.10.1038\/s42255-024-01093-w.2024","DOI":"10.1038\/s42255-024-01093-w"},{"issue":"7775","key":"6675_CR30","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","volume":"573","author":"V Venkataramani","year":"2019","unstructured":"Venkataramani, V. et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 573 (7775), 532\u2013538. https:\/\/doi.org\/10.1038\/s41586-019-1564-x (2019). \/09\/01 2019.","journal-title":"Nature"},{"key":"6675_CR31","doi-asserted-by":"crossref","unstructured":"Williams, R. S. B., Boison, D., Masino, S. A. & Rho, J. M. 1635Mechanisms of ketogenic diet action. In: (eds Rogawski, M. A., Noebels, J. L., Avoli, M., Rogawski, M. A., Vezzani, A. & Delgado-Escueta, A. V.) Jasper\u2019s Basic Mechanisms of the Epilepsies. (Oxford University Press, 2024).","DOI":"10.1093\/med\/9780197549469.003.0079"},{"key":"6675_CR32","doi-asserted-by":"publisher","unstructured":"Cohen, C. W., Fontaine, K. R., Arend, R. C. & Gower, B. A. A ketogenic diet is acceptable in women with ovarian and endometrial Cancer and has no adverse effects on blood lipids: A randomized, controlled trial. Nutrition Cancer 72(4) 584\u2013594 https:\/\/doi.org\/10.1080\/01635581.2019.1645864(2019).","DOI":"10.1080\/01635581.2019.1645864"},{"key":"6675_CR33","doi-asserted-by":"publisher","unstructured":"Schwartz, K. et al. Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer & Metabolism 3(1) 3 https:\/\/doi.org\/10.1186\/s40170-015-0129-1 (2015).","DOI":"10.1186\/s40170-015-0129-1"},{"issue":"4","key":"6675_CR34","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/01635581.2018.1460677","volume":"05","author":"KJ Martin-McGill","year":"2018","unstructured":"Martin-McGill, K. J., Marson, A. G., Tudur Smith, C. & Jenkinson, M. D. The modified ketogenic diet in adults with glioblastoma: an evaluation of feasibility and deliverability within the National health service. Nutr. Cancer. 05 (4), 643\u2013649. https:\/\/doi.org\/10.1080\/01635581.2018.1460677 (2018). \/19 2018.","journal-title":"Nutr. Cancer"},{"key":"6675_CR35","doi-asserted-by":"publisher","unstructured":"Cohen, C. W., Fontaine, K. R., Arend, R. C., Soleymani, T. & Gower, B. A. Favorable effects of a ketogenic diet on physical function, perceived energy, and food cravings in women with ovarian or endometrial cancer: A randomized, controlled trial. Nutrients Aug. 30 (9). https:\/\/doi.org\/10.3390\/nu10091187 (2018).","DOI":"10.3390\/nu10091187"},{"issue":"18","key":"6675_CR36","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.3390\/nu14183851","volume":"14","author":"S Dal Bello","year":"2022","unstructured":"Dal Bello, S. et al. Ketogenic diet in the treatment of gliomas and glioblastomas. Nutrients 14 (18), 3851 (2022).","journal-title":"Nutrients"},{"issue":"5","key":"6675_CR37","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/nu14051007","volume":"14","author":"B Sarga\u00e7o","year":"2022","unstructured":"Sarga\u00e7o, B., Oliveira, P. A., Antunes, M. L. & Moreira, A. C. Effects of the ketogenic diet in the treatment of gliomas: A systematic review. Nutrients 14 (5), 1007 (2022).","journal-title":"Nutrients"},{"issue":"1","key":"6675_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00394-021-02615-y","volume":"2022\/02\/01","author":"RJ Klement","year":"2022","unstructured":"Klement, R. J., Meyer, D., Kanzler, S. & Sweeney, R. A. Ketogenic diets consumed during radio-chemotherapy have beneficial effects on quality of life and metabolic health in patients with rectal cancer. Eur. J. Nutr. 2022\/02\/01 (1), 69\u201384. https:\/\/doi.org\/10.1007\/s00394-021-02615-y (2022).","journal-title":"Eur. J. Nutr."},{"key":"6675_CR39","doi-asserted-by":"publisher","unstructured":"Porper, K. et al. A Phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma. J. Neuro-Oncol.  153(3) 487\u2013496 https:\/\/doi.org\/10.1007\/s11060-021-03786-8(2021).","DOI":"10.1007\/s11060-021-03786-8"},{"issue":"9","key":"6675_CR40","doi-asserted-by":"publisher","first-page":"e953","DOI":"10.1212\/WNL.0000000000012386","volume":"97","author":"CS Karisa","year":"2021","unstructured":"Karisa, C. S. et al. Feasibility and biological activity of a Ketogenic\/Intermittent-Fasting diet in patients with glioma. Neurology 97 (9), e953. https:\/\/doi.org\/10.1212\/WNL.0000000000012386 (2021).","journal-title":"Neurology"},{"issue":"6","key":"6675_CR41","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3892\/ijo.2014.2382","volume":"44","author":"J Rieger","year":"2014","unstructured":"Rieger, J. et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J. Oncol Jun. 44 (6), 1843\u20131852. https:\/\/doi.org\/10.3892\/ijo.2014.2382 (2014).","journal-title":"Int J. Oncol Jun"},{"issue":"4","key":"6675_CR42","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.ijrobp.2020.06.021","volume":"15","author":"M Voss","year":"2020","unstructured":"Voss, M. et al. ERGO2: A prospective, randomized trial of Calorie-Restricted ketogenic diet and fasting in addition to reirradiation for malignant glioma. Int J. Radiat. Oncol. Biol. Phys Nov. 15 (4), 987\u2013995. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.06.021 (2020).","journal-title":"Int J. Radiat. Oncol. Biol. Phys Nov"},{"key":"6675_CR43","doi-asserted-by":"publisher","first-page":"175883591985395","DOI":"10.1177\/1758835919853958","volume":"11","author":"E van der Louw","year":"2019","unstructured":"van der Louw, E. et al. Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study. Ther. Adv. Med. Oncol. 11, 1758835919853958. https:\/\/doi.org\/10.1177\/1758835919853958 (2019).","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"6675_CR44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1743-7075-8-54","volume":"8","author":"M Schmidt","year":"2011","unstructured":"Schmidt, M., Pfetzer, N., Schwab, M., Strauss, I. & K\u00e4mmerer, U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr. Metabolism. 8 (1), 54. https:\/\/doi.org\/10.1186\/1743-7075-8-54 (2011). 2011\/07\/27.","journal-title":"Nutr. Metabolism"},{"issue":"1","key":"6675_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12937-020-00596-y","volume":"22","author":"A Khodabakhshi","year":"2020","unstructured":"Khodabakhshi, A., Seyfried, T. N., Kalamian, M., Beheshti, M. & Davoodi, S. H. Does a ketogenic diet have beneficial effects on quality of life, physical activity or biomarkers in patients with breast cancer: a randomized controlled clinical trial. Nutr J Aug. 22 (1), 87. https:\/\/doi.org\/10.1186\/s12937-020-00596-y (2020).","journal-title":"Nutr J Aug"},{"issue":"9","key":"6675_CR46","doi-asserted-by":"publisher","first-page":"e953","DOI":"10.1212\/WNL.0000000000012386","volume":"97","author":"KC Schreck","year":"2021","unstructured":"Schreck, K. C. et al. Feasibility and biological activity of a Ketogenic\/Intermittent-Fasting diet in patients with glioma. Neurology 97 (9), e953\u2013e963. https:\/\/doi.org\/10.1212\/WNL.0000000000012386 (2021).","journal-title":"Neurology"},{"issue":"2","key":"6675_CR47","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/epi4.12910","volume":"9","author":"C Griffen","year":"2024","unstructured":"Griffen, C. et al. Tolerance, adherence, and acceptability of a ketogenic 2.5:1 ratio, nutritionally complete, medium chain triglyceride-containing liquid feed in children and adults with drug-resistant epilepsy following a ketogenic diet. Epilepsia Open Apr. 9 (2), 727\u2013738. https:\/\/doi.org\/10.1002\/epi4.12910 (2024).","journal-title":"Epilepsia Open Apr"},{"issue":"11","key":"6675_CR48","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/j.1467-789X.2012.01021.x","volume":"13","author":"FL Santos","year":"2012","unstructured":"Santos, F. L., Esteves, S. S., da Costa Pereira, A., Yancy, W. S. Jr. & Nunes, J. P. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev Nov. 13 (11), 1048\u20131066. https:\/\/doi.org\/10.1111\/j.1467-789X.2012.01021.x (2012).","journal-title":"Obes Rev Nov"},{"key":"6675_CR49","doi-asserted-by":"publisher","unstructured":"Egashira, R. et al. Long-Term effects of a ketogenic diet for Cancer. Nutrients May. 16 (10). https:\/\/doi.org\/10.3390\/nu15102334 (2023).","DOI":"10.3390\/nu15102334"},{"issue":"8","key":"6675_CR50","doi-asserted-by":"publisher","first-page":"e9639","DOI":"10.7759\/cureus.9639","volume":"10","author":"JT Batch","year":"2020","unstructured":"Batch, J. T., Lamsal, S. P., Adkins, M., Sultan, S. & Ramirez, M. N. Advantages and disadvantages of the ketogenic diet: A review Article. Cureus Aug. 10 (8), e9639. https:\/\/doi.org\/10.7759\/cureus.9639 (2020).","journal-title":"Cureus Aug"},{"key":"6675_CR51","doi-asserted-by":"publisher","unstructured":"Acharya, P. et al. Incidence and characteristics of kidney stones in patients on ketogenic diet: A systematic review and Meta-Analysis. Diseases May. 25 (2). https:\/\/doi.org\/10.3390\/diseases9020039 (2021).","DOI":"10.3390\/diseases9020039"},{"issue":"7","key":"6675_CR52","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1017\/s0007114513000548","volume":"110","author":"NB Bueno","year":"2013","unstructured":"Bueno, N. B., de Melo, I. S., de Oliveira, S. L. & da Rocha Ataide, T. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J. Nutr Oct. 110 (7), 1178\u20131187. https:\/\/doi.org\/10.1017\/s0007114513000548 (2013).","journal-title":"Br J. Nutr Oct."},{"issue":"3","key":"6675_CR53","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/archinte.166.3.285","volume":"13","author":"AJ Nordmann","year":"2006","unstructured":"Nordmann, A. J. et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern. Med Feb. 13 (3), 285\u2013293. https:\/\/doi.org\/10.1001\/archinte.166.3.285 (2006).","journal-title":"Arch Intern. Med Feb"},{"issue":"3","key":"6675_CR54","doi-asserted-by":"publisher","first-page":"102402","DOI":"10.1016\/j.cpcardiol.2024.102402","volume":"49","author":"J Popiolek-Kalisz","year":"2024","unstructured":"Popiolek-Kalisz, J. Ketogenic diet and cardiovascular risk - state of the Art review. Curr Probl. Cardiol Mar. 49 (3), 102402. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102402 (2024).","journal-title":"Curr Probl. Cardiol Mar."},{"key":"6675_CR55","doi-asserted-by":"publisher","unstructured":"Patikorn, C. et al. Effects of ketogenic diet on health outcomes: an umbrella review of meta-analyses of randomized clinical trials. BMC Medicine. \/05\/25 2023;21(1):196. (2023). https:\/\/doi.org\/10.1186\/s12916-023-02874-y","DOI":"10.1186\/s12916-023-02874-y"},{"issue":"1","key":"6675_CR56","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1743-7075-8-54","volume":"8","author":"M Schmidt","year":"2011","unstructured":"Schmidt, M., Pfetzer, N., Schwab, M., Strauss, I. & K\u00e4mmerer, U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr Metab. (Lond) Jul. 8 (1), 54. https:\/\/doi.org\/10.1186\/1743-7075-8-54 (2011).","journal-title":"Nutr Metab. (Lond) Jul"},{"key":"6675_CR57","doi-asserted-by":"crossref","unstructured":"Seyfried, T. N. et al. Ketogenic metabolic therapy, without chemo or radiation, for the long-term management of IDH1-mutant glioblastoma: an 80-month follow-up case report. Front. Nutr. 281. (2021).","DOI":"10.3389\/fnut.2021.682243"},{"key":"6675_CR58","doi-asserted-by":"publisher","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl. J. Med. 352 (10), 987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330 (2005).","DOI":"10.1056\/NEJMoa043330"},{"issue":"7","key":"6675_CR59","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3346\/jkms.2014.29.7.980","volume":"29","author":"SH Bae","year":"2014","unstructured":"Bae, S. H. et al. Toxicity profile of Temozolomide in the treatment of 300 malignant glioma patients in Korea. J Korean Med. Sci Jul. 29 (7), 980\u2013984. https:\/\/doi.org\/10.3346\/jkms.2014.29.7.980 (2014).","journal-title":"J Korean Med. Sci Jul"},{"key":"6675_CR60","unstructured":"Scott, N. W. et al. EORTC QLQ-C30 reference values manual. (2008)."},{"issue":"8","key":"6675_CR61","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/neuonc\/noab037","volume":"2","author":"L Dirven","year":"2021","unstructured":"Dirven, L. et al. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. Neuro Oncol Aug. 2 (8), 1327\u20131336. https:\/\/doi.org\/10.1093\/neuonc\/noab037 (2021).","journal-title":"Neuro Oncol Aug"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06675-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06675-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06675-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:37:59Z","timestamp":1751369879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06675-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6675"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06675-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Internal monitoring visits were performed by the Quality Management Core of the Cedars-Sinai Cancer Clinical Trials Office and reviewed by the Institutional Data and Safety Monitoring Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"21064"}}